HK1209104A1 - Vegfr3 inhibitors vegfr3 - Google Patents
Vegfr3 inhibitors vegfr3Info
- Publication number
- HK1209104A1 HK1209104A1 HK15109686.3A HK15109686A HK1209104A1 HK 1209104 A1 HK1209104 A1 HK 1209104A1 HK 15109686 A HK15109686 A HK 15109686A HK 1209104 A1 HK1209104 A1 HK 1209104A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vegfr3
- inhibitors
- vegfr3 inhibitors
- inhibitors vegfr3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261684254P | 2012-08-17 | 2012-08-17 | |
PCT/AU2013/000912 WO2014026242A1 (en) | 2012-08-17 | 2013-08-16 | Vegfr3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209104A1 true HK1209104A1 (en) | 2016-03-24 |
Family
ID=50101125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15109686.3A HK1209104A1 (en) | 2012-08-17 | 2015-10-02 | Vegfr3 inhibitors vegfr3 |
Country Status (8)
Country | Link |
---|---|
US (2) | US9266864B2 (ja) |
EP (1) | EP2885292A4 (ja) |
JP (1) | JP2015524825A (ja) |
CN (2) | CN104837835A (ja) |
AU (1) | AU2013302319A1 (ja) |
CA (1) | CA2882270A1 (ja) |
HK (1) | HK1209104A1 (ja) |
WO (1) | WO2014026242A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015123722A1 (en) * | 2014-02-19 | 2015-08-27 | Bionomics Limited | Inhibitors |
WO2017100861A1 (en) | 2015-12-16 | 2017-06-22 | The Walter And Eliza Hall Institute Of Medical Research | Inhibition of cytokine-induced sh2 protein in nk cells |
EP4026849A1 (en) * | 2016-09-26 | 2022-07-13 | Ensemble Group Holdings | Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems using a combination of vegfr-3 and pd-1 or pd-l1 inhibitors |
JP2020503255A (ja) * | 2016-10-27 | 2020-01-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンアルファ9の遮断はリンパ弁形成を抑制し、移植片の生存を促進する |
CA3048376A1 (en) | 2016-12-27 | 2018-07-05 | Riken | Bmp-signal-inhibiting compound |
CN109942616A (zh) * | 2019-04-18 | 2019-06-28 | 广东工业大学 | 一种含炔基的芳基酰胺类衍生物及其制备方法和应用 |
CN114853740B (zh) * | 2021-02-03 | 2023-08-01 | 药雅科技(上海)有限公司 | 炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2463989C (en) | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
TW200922590A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
CA2742897A1 (en) | 2008-11-06 | 2010-05-14 | Astrazeneca Ab | Modulators of amyloid beta. |
AU2009322270B2 (en) * | 2008-12-05 | 2014-12-18 | Abbvie Bahamas Ltd | Thieno [3, 2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer |
WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
EP2429520A1 (en) * | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | New combination therapy in treatment of oncological and fibrotic diseases |
DE102010034699A1 (de) | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
EP2616057A4 (en) * | 2010-09-14 | 2014-03-12 | Glaxosmithkline Ip No 2 Ltd | COMBINATION OF B-RAF AND VEGFR INHIBITORS |
CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
AU2012216893B2 (en) * | 2011-02-17 | 2016-08-11 | Cancer Therapeutics Crc Pty Limited | FAK inhibitors |
KR101682417B1 (ko) | 2011-02-25 | 2016-12-06 | 주식회사유한양행 | 다이아미노피리미딘 유도체 및 그의 제조방법 |
US9376432B2 (en) | 2012-07-17 | 2016-06-28 | Sanofi | Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma |
WO2014027199A1 (en) * | 2012-08-14 | 2014-02-20 | Cancer Therapeutics Crc Pty Ltd | Fak and flt3 inhibitors |
AU2013302320A1 (en) | 2012-08-17 | 2015-02-26 | Cancer Therapeutics Crc Pty Limited | VEGFR3 inhibitors |
CN103113355B (zh) | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
-
2013
- 2013-08-16 AU AU2013302319A patent/AU2013302319A1/en not_active Abandoned
- 2013-08-16 JP JP2015526835A patent/JP2015524825A/ja active Pending
- 2013-08-16 EP EP13829826.0A patent/EP2885292A4/en not_active Withdrawn
- 2013-08-16 US US13/968,932 patent/US9266864B2/en not_active Expired - Fee Related
- 2013-08-16 US US14/422,084 patent/US20150225377A1/en not_active Abandoned
- 2013-08-16 CN CN201380052157.2A patent/CN104837835A/zh active Pending
- 2013-08-16 CN CN201710144110.9A patent/CN106986832A/zh active Pending
- 2013-08-16 WO PCT/AU2013/000912 patent/WO2014026242A1/en active Application Filing
- 2013-08-16 CA CA2882270A patent/CA2882270A1/en not_active Abandoned
-
2015
- 2015-10-02 HK HK15109686.3A patent/HK1209104A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN106986832A (zh) | 2017-07-28 |
CA2882270A1 (en) | 2014-02-20 |
US20140080798A1 (en) | 2014-03-20 |
CN104837835A (zh) | 2015-08-12 |
JP2015524825A (ja) | 2015-08-27 |
AU2013302319A1 (en) | 2015-02-26 |
WO2014026242A1 (en) | 2014-02-20 |
EP2885292A4 (en) | 2015-07-01 |
US9266864B2 (en) | 2016-02-23 |
US20150225377A1 (en) | 2015-08-13 |
EP2885292A1 (en) | 2015-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201504200B (en) | Beta-lactamase inhibitors | |
IL237011A0 (en) | Dihydropyridone p1 as factor xia inhibitors | |
HK1208363A1 (en) | New methods | |
IL237012A0 (en) | Dihydropyridone p1 as factor xia inhibitors | |
HK1201200A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
HK1200830A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
HK1207366A1 (en) | Thiadiazolidinediones as gsk-3 inhibitors gsk-3 | |
GB201211310D0 (en) | CSF-1R kinase inhibitors | |
HK1206724A1 (en) | Substituted benzothienopyrimidines | |
SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
HK1209105A1 (en) | Vegfr3 inhibitors vegfr3 | |
HK1209104A1 (en) | Vegfr3 inhibitors vegfr3 | |
HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
EP2934541A4 (en) | NORIBOGAINE SUBSTITUTE | |
HK1206022A1 (zh) | 取代的咪唑並噠嗪 | |
EP2847201A4 (en) | 6-oxo-purin-phosphoribosyl INHIBITORS | |
HK1212895A1 (zh) | 用於免疫調節的沙奎那韋- | |
GB201213825D0 (en) | Damper-device for bouncing-device |